In particular, palbociclib received an accelerated approval for the treatment of postmenopausal women exhibiting ER-positive and HER2-negative advanced BC on the basis of the results obtained by PALOMA-1 and PALOMA-2 clinical trials [23, 24]. This evidence concerns the gene ESR1 and breast cancer.